mRNA technologies. What is their future and scope, and what are the challenges that countries might face in rolling them out? Hello and welcome to Science in5. I'm Vismita Gupta-Smith. We are talking to Dr.Soumya Swaminathan today. Soumya, talk to us about mRNA technologies. What is the future?
Practical guide for doctors, nurses,laboratory technicians, medical auxiliaries,water and sanitation specialists and logisticians. Online version
Guide pratique à l’usage des médecins, infirmiers, techniciens de laboratoire, auxiliaires de santé, techniciens sanitaires et logisticiens
2023 will mark the 75th year of the World Health Organization. The world has achieved many public health milestones in these 75 years. In Science in 5 today we will take a look into the future - to understand what are the innovations we can expect and what will be some of our biggest challenges. Her...e to paint us a picture of what Health for All would look like in the future is WHO's Chief Scientist, Dr Soumya Swaminathan.
more
Canadian Journal of Microbiology 25 June 2021 https://doi.org/10.1139/cjm-2020-0572
Microbes like bacteria, fungus and viruses are becoming resistant to medicines like antibiotics. WHO has declared antimicrobial resistance as a global health and developmental threat. How can we stop antimicrobial resistance? Dr Hanan Balkhy explains in Science in 5
Education and information about Chagas Disease epidemiology and risk factors.
Leishmaniasis is a major vector-borne disease caused by obligate intramacrophage protozoa of the genus Leishmania, and transmitted by the bite of phlebotomine female sand flies of the genera Phlebotomus and Lutzomyia, in the old and new worlds, respectively. Among 20 well-recognized Leishmania speci...es known to infect humans, 18 have zoonotic nature, which include agents of visceral, cutaneous, and mucocutaneous forms of the disease, in both the old and new worlds. Currently, leishmaniasis show a wider geographic distribution and increased global incidence. Environmental, demographic and human behaviors contribute to the changing landscape for zoonotic cutaneous and visceral leishmaniasis. The primary reservoir hosts of Leishmania are sylvatic mammals such as forest rodents, hyraxes and wild canids, and dogs are the most important species among domesticated animals in the epidemiology of this disease. These parasites have two basic life cycle stages: one extracellular stage within the invertebrate host (phlebotomine sand fly), and one intracellular stage within a vertebrate host. Co-infection with HIV intensifies the burden of visceral and cutaneous leishmaniasis by causing severe forms and more difficult to manage. The disease is endemic to Ethiopia, and the clinical signs are not pathognomic. The visceral form (Kala-azar) may be confused with other similar conditions such as malaria, tropical splenomegaly, schistosomiasis, milliary tuberculosis, and brucellosis. Similarly, cutaneous leishmaniasis should be differentiated from disease like tropical ulcers, impetigo and leprosy. There are several methods of laboratory diagnosis of leishmaniasis, including parasitological, immunological and molecular. Different forms of treatments are available including oral, parenteral, and topical medications such as pentavalent antimonials, liposomal amphotericin B, miltefosine and paromomycin. Methods of control are largely limited to destruction of animal reservoirs, treatment of infected humans, and management of sand fly populations. Development of an effective vaccine against leishmaniasis has been largely unsuccessful and hinders its prevention.
more
Leishmaniasis is found in people in focal areas of approximately 90 countries in the tropics, subtropics, and southern Europe. The ecologic settings range from rain forests to deserts. Leishmaniasis usually is more common in rural than in urban areas, but it is found in the outskirts of some cities.... Climate and other environmental changes have the potential to expand the geographic range of the sand fly vectors and the areas in the world where leishmaniasis is found.
more
Training in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis: learners’ guide. World Health Organization.
Lymphatic filariasis (LF) is an avoidable, debilitating, disfiguring disease caused by infection with the filarial parasites Wuchereria bancrofti, Brugia malayi and B. timori. Globally, 51.4 million people are
estimated to be infected. Lymphoedema and hydrocoele are the visible, chronic clinical co...nsequences of the lymphatic vessel impairment caused by infection with these parasites. Mosquitos in the genera Culex, Anopheles, Mansonia and Aedes transmit the parasites from person to person. 2020 marked the 20th year since WHO established the Global Programme to Eliminate Lymphatic Filariasis (GPELF) which aims to stop transmission of infection with mass drug administration (MDA) and to alleviate suffering among people affected by the disease through morbidity management and disability prevention (MMDP).
more
La filariose lymphatique (FL) est une maladie évitable, incapacitante et défigurante, due à une infestation par des filaires parasites des espèces Wuchereria bancrofti, Brugia malayi et B. timori. On estime que 51,4 millions de personnes sont infectées dans le monde. Le lymphœdème et l’hydr...ocèle sont les conséquences cliniques chroniques visibles de l’altération des vaisseaux lymphatiques causée par la présence de
ces parasites dans l’organisme. Les parasites sont transmis d’une personne à l’autre par l’intermédiaire de moustiques des genres Culex, Anopheles, Mansonia et Aedes. L’année 2020 a marqué la 20e année du Programme mondial pour l’élimination de la filariose lymphatique (GPELF) établi par l’OMS, dont l’objectif est de mettre fin à la transmission de l’infection grâce à l’administration de masse de médicaments
(AMM) et d’alléger les souffrances des malades par la prise en charge de la morbidité et la prévention des incapacités (PMPI).
more
Website last accessed on 04.06.2023
Youtube Video
Effective monitoring, epidemiological assessment and evaluation are necessary to achieve the aim of interrupting LF transmission. This manual is designed to ensure that national elimination programmes have available the best information on methodologies and procedures for monitoring MDA, appropriate...ly assessing when infection has been reduced to levels where transmission is likely no longer sustainable, implementing adequate surveillance after MDA has ceased to determine whether recrudescence has occurred, and preparing for verification of the absence of transmission. The manual provides general guidance to national programmes; relevant background information on technical issues is contained in the annexes. As real-life situations may not correspond to predefined categories, consultation with WHO and experts is recommended in complicated situations.
more
Monitoramento efetivo, avaliação epidemiológica e análise subsequente são
necessários para atingir o objetivo de interromper a transmissão da FL. Este manual foi
elaborado para oferecer aos programas nacionais de eliminação da fi lariose informação de qualidade sobre metodologias e proc...edimentos para monitoramento dos TC, avaliação adequada sobre se e quando ocorreu redução da infecção a níveis em que a transmissão provavelmente não é mais sustentável, implementação de vigilância adequada após a interrupção dos TCs para estabelecer se está ocorrendo recrudescência e medidas para comprovação da ausência de transmissão. O Manual oferece orientação geral aos programas nacionais e informações relevantes sobre questões técnicas são apresentadas nos anexos. Como as circunstâncias da vida real podem não corresponder a categorias pré-defi nidas, recomenda-se que se consultem a OMS e especialistas em situações complexas.
more
CEPI is seeking to raise $3.5 billion to implement CEPI’s next 5-year plan. To mitigate the immediate threat of COVID-19 variants, it is activating key elements of this plan now—and seeking to mobilise a portion of this $3.5 billion in 2021. We have already launched R&D programmes to initiate de...velopment of next-generation vaccines against COVID-19 variants and we are planning studies to answer critical scientific questions related to the durability of immunity, effectiveness of mixed-vaccine regimens, and vaccine effectiveness in vulnerable populations such as pregnant women. We are also bringing forward our plans to develop vaccines that could protect against multiple COVID-19 variants and other coronavirus specie
more
Response to the Periodic Epidemic
Cholera is a transmissible diarrhoeal infection caused by Vibrio cholerae. Endemic and/or epidemic in over 40 countries (mainly in Africa and Asia), cholera continues to be a major global public health issue.
The World Health Organization (WHO) estimates that the number of cases reported worldwid...e represents in reality only 5 to 10% of actual cases.
This guide is intended for medical and non-medical staff responding to a cholera outbreak. It attempts to provide concrete answers to the questions and problems faced by staff, based on the recommendations of reference organisations, such as WHO and UNICEF, as well as Médecins Sans Frontières’ experience in the field.
It is divided into 8 chapters. Chapter 1, Cholera overview, outlines the epidemiological and clinical features of cholera. Chapter 2, Outbreak investigation, explains the method and stages of a field investigation, from the alert to implementation of initial activities. Chapter 3, Cholera control measures, details measures and tools to prevent and/or control cholera transmission and mortality in populations affected, or at risk of being affected, by an epidemic (curative care, prevention means and health promotion activities). Chapter 4, Strategies for epidemic response, addresses the roll-out strategies of the measures described in Chapter 3 which depend on context (e.g. urban, rural, endemic, non-endemic setting, etc.), resources and particular constraints. Chapter 5, Cholera case management, details the different stages of cholera treatment, from diagnosis through to cure.
Chapter 6, Setting up cholera treatment facilities, focuses on the installation of treatment facilities that vary in size and complexity according to operational requirements (treatment centres and units and oral rehydration points). Chapter 7, Organisation of cholera treatment facilities, describes the organisation of these specialized facilities in terms of human resources, supply, water, hygiene and sanitation, etc. Chapter 8, Monitoring and evaluation, presents the key data to be collected and analysed during an epidemic to facilitate a tailored response and evaluate its quality and effectiveness.
The guide includes various practical tools in the appendices to facilitate activities (e.g. water quality tests, job descriptions, documents, etc.). Moreover, the toolbox also contains additional tools in editable formats (individual patient file, cholera case register, pictograms).
Despite all efforts, it is possible that certain errors may have been overlooked in this guide. Please inform the authors of any errors detected.
To ensure that this guide continues to evolve while remaining adapted to field realities, please send any comments or suggestions.
more
ver the past 15 years, dengue fever, an endemic disease in the country, has triggered significant epidemics in 2010, 2019, and most recently in 2023. This year, due to the escalating number of reported cases, the Secretariat of Health (SESAL) issued an epidemiological alert in February. By March, th...e incidence of cases had escalated to epidemic proportions.
more